Which dopaminergic therapy is most effective for symptomatic management of Parkinson disease?

• A. Selegiline
• B. Bromocriptine
• C. Amantadine
• D. Levodopa

Answer: (D)

Levodopa provides the strongest, most reliable improvement of motor symptoms in Parkinson disease because it directly replenishes dopamine in the brain. It crosses the blood–brain barrier and is converted to dopamine where it’s needed, addressing the core dopaminergic deficit that drives bradykinesia, rigidity, and tremor. When given with carbidopa, peripheral conversion is blocked, which increases brain availability and reduces nausea and other peripheral side effects, making it both more effective and better tolerated.

Other dopaminergic therapies contribute in helpful ways but don’t match levodopa’s level of symptom relief. Selegiline slows dopamine breakdown and can offer modest improvement or delay levodopa need, but isn’t as potent for motor symptoms. Bromocriptine, a dopamine agonist, can help but is generally less effective long-term and carries more side effects. Amantadine can aid mild symptoms and reduce dyskinesias, but its impact on overall motor function is more limited.

So, while levodopa therapy often becomes the cornerstone of treatment for symptomatic management, clinicians also monitor for long-term complications like motor fluctuations and dyskinesias that can arise with extended use.